Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052594 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3475766 in Healthy Participants
A Phase 1 study of Dyslipidemias, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT04052594: Completed Phase 1 study of Dyslipidemias, sponsored by Eli Lilly and Company.
NCT04052594 is a Phase 1 study of Dyslipidemias that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04052594, a Phase 1 study of Dyslipidemias, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be documented. This study will last up to 16 weeks for each participant.
Primary Outcome
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Conditions Studied
Interventions
- DRUG LY3475766 - IV
- DRUG LY3475766 - SC
- DRUG Placebo - IV
- DRUG Placebo - SC
Study Locations (4)
California
- WCCT Global - Cypress
Florida
- Covance Clinical Research Inc - Daytona Beach
Texas
- Covance Dallas - Dallas
Wisconsin
- Covance Clinical Research Inc - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
What the finished NCT04052594 record still lists
NCT04052594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 4 interventions - of which LY3475766 - IV is the first listed.
NCT04052594 reports a single indexed study location in California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04052594 about?
NCT04052594 is a clinical study titled "A Study of LY3475766 in Healthy Participants". This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be doc...
What is the current status of trial NCT04052594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-09-03. Estimated completion is 2021-03-31.
What conditions does trial NCT04052594 study?
This clinical trial studies the following conditions: Dyslipidemias.
What interventions are being tested in trial NCT04052594?
The interventions under investigation include: LY3475766 - IV (DRUG), LY3475766 - SC (DRUG), Placebo - IV (DRUG), Placebo - SC (DRUG).
Who is sponsoring clinical trial NCT04052594?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04052594 being conducted?
This trial has 4 study locations across California, Florida, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04052594's enrollment target sits among peer trials
48 22nd of 28 higher than 7 of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
COMPLETED · Phase 1
-
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI